Hurdles and Complexities of Codon 13 KRAS Mutations
Cet article analyse la complexité des enjeux associés à la validation des travaux sur les mutations du codon 13 du gène KRAS comme biomarqueur de la réponse à un anticorps monoclonal anti EGFR pour le traitement d'un cancer colorectal
The history of biomarker development for epidermal growth factor receptor (EGFR) monoclonal antibodies for patients with colorectal cancer has been a convoluted path. Each development has provided increased recognition that there is still much to learn about biomarkers for EGFR monoclonal antibodies in colorectal cancer. In the article that accompanies this editorial, Tejpar et al provide an added chapter to this complex issue and raise important questions about the level of evidence that we should require before implementing predictive biomarkers in clinical practice...
Journal of Clinical Oncology , éditorial en libre accès, 2012